Liquidia Corporation Q3 2025 Earnings Recap

LQDA Q3 2025 November 5, 2025

Get alerts when LQDA reports next quarter

Liquidia Corporation achieved a significant operational breakthrough in Q3 2025, with YUTREPIA generating $51.7 million in net sales during its first full quarter post-launch, positioning the company ahead of profitability expectations.

Earnings Per Share Beat

$-0.04 vs $-0.45 est.

+91.1% surprise

Revenue Miss

54342000 vs 80722830 est.

-32.7% surprise

Market Reaction

1-Day -5.34%

5-Day -2.33%

30-Day +16.91%

See LQDA alongside your other holdings

Add to your portfolio — free

Key Takeaways

YUTREPIA received over 2,000 unique prescriptions and initiated therapy for more than 1,500 patients within its first full quarter.
Positive adjusted EBITDA of $10.1 million marked a faster path to profitability than anticipated, with net cash flow becoming positive for the first month in September.
Approximately 75% of YUTREPIA patients are new to treprostinil, indicating strong market penetration and physician acceptance.
Liquidia plans to expand YUTREPIA's clinical utility via open-label studies and research into other potential indications like IPF and PPF.
Company's cash position strengthened with $157.5 million on hand, allowing for continued investment in innovation.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit LQDA on AllInvestView.

Previous Q2 2025